REGENERON PHARMACEUTICALS, INC. Revenue from Related Parties
REGENERON PHARMACEUTICALS, INC. (REGN) reported Revenue from Related Parties of $189.49 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2018-05-03
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2018-03-31 was $189.49M, a 9.92% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2017-12-31 was $199.52M, a 52.12% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2017-09-30 was $245.18M, a 69.80% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2017-06-30 was $222.13M, a 35.93% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for fiscal 2017 was $877.19M, a 33.18% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for fiscal 2016 was $658.66M, a 13.20% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for fiscal 2015 was $758.87M, a 40.19% increase from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. revenue from related parties for fiscal 2014 was $541.30M, a 25.85% increase from fiscal 2013.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2018-03-31 | $189.49M 10-Q · filed 2018-05-03 | $389.01M derived: sum of 2 quarters · filed 2018-05-03 | $634.19M derived: sum of 3 quarters · filed 2018-05-03 | $856.32M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-12-31 | $199.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $444.70M derived: sum of 2 quarters · filed 2018-02-08 | $666.83M derived: sum of 3 quarters · filed 2018-02-08 | $877.19M 10-K · filed 2018-02-08 |
| 2017-09-30 | $245.18M 10-Q · filed 2017-11-08 | $467.30M derived: sum of 2 quarters · filed 2017-11-08 | $677.67M 10-Q · filed 2017-11-08 | $808.84M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-06-30 | $222.13M 10-Q · filed 2017-08-03 | $432.50M 10-Q · filed 2017-08-03 | $563.66M derived: sum of 3 quarters · filed 2018-05-03 | $708.05M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-03-31 | $210.37M 10-Q · filed 2018-05-03 | $341.53M derived: sum of 2 quarters · filed 2018-05-03 | $485.92M derived: sum of 3 quarters · filed 2018-05-03 | $649.34M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $131.16M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $275.56M derived: sum of 2 quarters · filed 2018-02-08 | $438.97M derived: sum of 3 quarters · filed 2018-02-08 | $658.66M 10-K · filed 2018-02-08 |
| 2016-09-30 | $144.39M 10-Q · filed 2017-11-08 | $307.81M derived: sum of 2 quarters · filed 2017-11-08 | $527.50M 10-Q · filed 2017-11-08 | $693.17M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-06-30 | $163.41M 10-Q · filed 2017-08-03 | $383.11M 10-Q · filed 2017-08-03 | $548.78M derived: sum of 3 quarters · filed 2018-02-08 | $773.51M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-03-31 | $219.69M 10-Q · filed 2017-05-04 | $385.37M derived: sum of 2 quarters · filed 2018-02-08 | $610.10M derived: sum of 3 quarters · filed 2018-02-08 | $805.21M derived: sum of 4 quarters · filed 2018-02-08 |
| 2015-12-31 | $165.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $390.41M derived: sum of 2 quarters · filed 2018-02-08 | $585.52M derived: sum of 3 quarters · filed 2018-02-08 | $758.87M 10-K · filed 2018-02-08 |
| 2015-09-30 | $224.74M 10-Q · filed 2016-11-04 | $419.85M derived: sum of 2 quarters · filed 2016-11-04 | $593.20M 10-Q · filed 2016-11-04 | $728.47M derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-06-30 | $195.11M 10-Q · filed 2016-08-04 | $368.47M 10-Q · filed 2016-08-04 | $503.74M derived: sum of 3 quarters · filed 2017-02-09 | $636.66M derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-03-31 | $173.36M 10-Q · filed 2016-05-05 | $308.63M derived: sum of 2 quarters · filed 2017-02-09 | $441.55M derived: sum of 3 quarters · filed 2017-02-09 | $584.15M derived: sum of 4 quarters · filed 2017-02-09 |
| 2014-12-31 | $135.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $268.20M derived: sum of 2 quarters · filed 2017-02-09 | $410.79M derived: sum of 3 quarters · filed 2017-02-09 | $541.30M 10-K · filed 2017-02-09 |
| 2014-09-30 | $132.93M 10-Q · filed 2015-11-04 | $275.52M derived: sum of 2 quarters · filed 2015-11-04 | $406.03M 10-Q · filed 2015-11-04 | $516.98M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $142.59M 10-Q · filed 2015-08-04 | $273.10M 10-Q · filed 2015-08-04 | $384.05M derived: sum of 3 quarters · filed 2016-02-11 | $518.41M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $130.51M 10-Q · filed 2015-05-07 | $241.46M derived: sum of 2 quarters · filed 2016-02-11 | $375.82M derived: sum of 3 quarters · filed 2016-02-11 | $461.35M derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $110.95M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $245.31M derived: sum of 2 quarters · filed 2016-02-11 | $330.84M derived: sum of 3 quarters · filed 2016-02-11 | $430.11M 10-K · filed 2016-02-11 |
| 2013-09-30 | $134.36M 10-Q · filed 2014-11-04 | $219.89M derived: sum of 2 quarters · filed 2014-11-04 | $319.16M 10-Q · filed 2014-11-04 | $423.94M derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-06-30 | $85.53M 10-Q · filed 2014-08-05 | $184.80M 10-Q · filed 2014-08-05 | $289.58M derived: sum of 3 quarters · filed 2015-02-12 | $434.62M derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-03-31 | $99.27M 10-Q · filed 2014-05-08 | $204.05M derived: sum of 2 quarters · filed 2015-02-12 | $349.09M derived: sum of 3 quarters · filed 2015-02-12 | $438.08M derived: sum of 4 quarters · filed 2015-02-12 |
| 2012-12-31 | $104.78M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $249.82M derived: sum of 2 quarters · filed 2015-02-12 | $338.81M derived: sum of 3 quarters · filed 2015-02-12 | $423.81M 10-K · filed 2015-02-12 |
| 2012-09-30 | $145.04M 10-Q · filed 2013-11-05 | $234.03M derived: sum of 2 quarters · filed 2013-11-05 | $319.04M 10-Q · filed 2013-11-05 | |
| 2012-06-30 | $88.99M 10-Q · filed 2013-08-06 | $173.99M 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | $85.00M 10-Q · filed 2013-05-03 | |||
| 2011-12-31 | $326.61M 10-K · filed 2014-02-13 | |||
| 2010-12-31 | $311.33M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |